Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly
You may also be interested in...
Merck And Cipla Bury Differences To Co-market Raltegravir In India
Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.
India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.
India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.